Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2012. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
| Metric | Value as of Oct 31, 2012 |
|---|---|
| Issued Ordinary Shares (25p each) | 5,445,349,024 |
| Treasury Shares | 516,290,427 |
| Total Voting Rights | 4,929,058,597 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data from previous periods is included in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of share capital status rather than a financial performance report.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,929,058,597) to determine disclosure thresholds under Financial Services Authority rules.
- Confirm the number of shares held in Treasury (516,290,427) when calculating outstanding share counts.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.